Implications of Patient-Reported Outcome Measures among patients with recently diagnosed type 2 diabetes

Table 1 Socio-demographic and clinical characteristics of the study population (n = 392)

Variable	Percent or mean ± SD
Age (years)	60.5 ± 8.1
Age categories (%)
48.0–55.0	31.9
55.1–64.9	35.2
65.0–84.0	32.9
Female (%)	41.3
Israeli-born (%)	69.9
Arab (%)	18.9
Married/cohabited (%)	81.6
Socioeconomic position	5.8 ± 2.2
Never smokers (%)	49.2
Education
< 12 years (%)	19.9
12 years (%)	34.4
> 12 years (%)	45.7
Diabetes duration	2.7 ± 1.0
Anti-diabetic medications^b (%)	73.0
Comorbidities^a (%)	29.8
Process indicators- performance in 2017 (%)
HbA1c	92.9
LDL-cholesterol	93.6
Blood pressure	91.6
Serum creatinine	94.1
Urinary protein	91.6
Eye clinic visit	52.6
Influenza vaccination	41.8
Process indicators- composite score in 2017 (%)
0–4	10.7
5	25.0
6	41.8
7	22.4
Intermediate-outcome indicators- controlled in 2017 (%)
HbA1c (≤ 7%/ ≤ 8%)*	71.9
LDL-cholesterol ≤ 100 mg/dL	49.0
Blood pressure ≤ 140/90 mmHg	76.5

LDL-cholesterol: low density lipoprotein cholesterol
^aComorbidities included: cardiac disease, retinopathy, visual loss, end stage renal disease or lower limb amputation based on diagnosis and procedures
^bOral hypoglycemic medications (none was treated with insulin)
*HbA1c ≤ 7% for patients aged ≤ 74 years and HbA1c ≤ 8% for patients aged ≥ 75 years. Among patients who were treated with anti-diabetic medications 75.0% had a controlled level of HbA1c (≤ 7%/ ≤ 8%)

ISSN: 2045-4015